Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Not yet recruitingOBSERVATIONAL

Enrollment

900

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2032

Study Completion Date

December 31, 2033

Conditions

Breast CancerTNBC - Triple-Negative Breast CancerHR Positive/HER-2 Negative Breast CancerHER2 + Breast CancerEarly Stage Breast Cancer

Interventions

OTHER

There are no interventions in this observational study.

All Listed Sponsors

lead

Tempus AI

INDUSTRY